Milea Timbergen

202 22 . van Broekhoven DL, Verhoef C, Grunhagen DJ, et al. Prognostic value of CTNNB1 gene mutation in primary sporadic aggressive fibromatosis. Ann Surg Oncol 2015; 22(5):1464-70. 23 . Colombo C, Miceli R, Lazar AJ, et al. CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study. Cancer 2013; 119(20):3696-702. 24 . Garvey PB, Booth JH, Baumann DP, et al. Complex reconstruction of desmoid tumor resections does not increase desmoid tumor recurrence. Journal of the American College of Surgeons 2013; 217(3):472-480. 25 . Domont J, Salas S, Lacroix L, et al. High frequency of beta-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management. Br J Cancer 2010; 102(6):1032-6. 26 . PROSPERO Iprosr, National Institue for Health Research, Centre for Reviews and Dissemination University of York. 2018. Accessed 11-12-2018, 2018. 27 . Howick J, Chalmers I, Glasziou P, et al. The Oxford 2011 Levels of Evidence. OCEBM Levels of Evidence Working Group, 2011. 28 . Hayden JA, van der Windt DA, Cartwright JL, et al. Assessing bias in studies of prognostic factors. Ann Intern Med 2013; 158(4):280-6. 29 . Erben P, Nowak D, Sauer C, et al. Molecular analysis of desmoid tumors with a high-density single-nucleotide polymorphism array identifies new molecular candidate lesions. Onkologie 2012; 35(11):684-689. 30 . Kamali F, Wang WL, Guadagnolo BA, et al. MRI may be used as a prognostic indicator in patients with extra-abdominal desmoid tumours. Br J Radiol 2016; 89(1058):20150308. 31 . Salas S, Brulard C, Terrier P, et al. Gene Expression Profiling of Desmoid Tumors by cDNA Microarrays and Correlation with Progression-Free Survival. Clin Cancer Res 2015; 21(18):4194-200. 32 . Colombo C, Belfiore A, Paielli N, et al. beta-catenin in Desmoid-Type Fibromatosis: deep insights on the role of T41A and S45F mutations on protein structure and gene expression. Mol Oncol 2017. 33 . Colombo C, Creighton CJ, Ghadimi MP, et al. Increased midkine expression correlates with desmoid tumour recurrence: a potential biomarker and therapeutic target. J Pathol 2011; 225(4):574-82. 34 . Huss S, Nehles J, Binot E, et al. beta-catenin (CTNNB1) mutations and clinicopathological features of mesenteric desmoid-type fibromatosis. Histopathology 2013; 62(2):294-304. 35 . Romero S, Szafranska J, Cabrera E, et al. Role of macrophages and tumor angiogenesis in desmoid-type fibromatosis. Laboratory Investigation 2012; 92((Romero S.; Szafranska J.; Cabrera E.; Gonzalez A.; Peiro A.; Llauger J.; Ortega L.; Bague S.; Canet B.; Espinosa I.; Prat J.) Hospital de la Santa Creu i Sant Pau, Institute of Biomedical Research (IIB Sant Pau), Autonomous University of Barcelona, Barcelona, Spain):19A. 36 . Penel N, Le Cesne A, Bonvalot S, et al. Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group. Eur J Cancer 2017; 83:125-131. 37 . Huang K, Fu H, Shi YQ, et al. Prognostic factors for extra-abdominal and abdominal wall desmoids: A 20-year experience at a single institution. Journal of Surgical Oncology 2009; 100(7):563-569. 38 . Rock MG, Pritchard DJ, Reiman HM, et al. Extra-abdominal desmoid tumors. J Bone Joint Surg Am 1984; 66(9):1369-74. 39 . Ballo MT, Zagars GK, Pollack A, et al. Desmoid tumor: Prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. Journal of Clinical Oncology 1999; 17(1):158-167. 40 . Salas S, Dufresne A, Bui B, et al. Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation. J Clin Oncol 2011; 29(26):3553-8. 41 . Mussi CE, Colombo P, Lo Russo C, et al. Sporadic desmoid tumors of the abdominal wall: the results of surgery. Tumori 2016; 102(6):582-587. 42 . Nishida Y, Tsukushi S, Urakawa H, et al. Simple resection of truncal desmoid tumors: A case series. Oncol Lett 2016; 12(2):1564-1568. 7